TrialClinical cancer research : an official journal of the American Association for Cancer Research2021

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.

Paolo A Ascierto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.